Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-09-01

Clinical Trial Update: A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine [Phase 1]

View source ↗

Summary

Phase 1 study assessing lasmiditan in children 6 to 17 with migraine has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lasmiditan (Lasmiditan)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Migraine | Phase 1 | Status: COMPLETED | Results posted: 2020-09-01